Table 1 Baseline demographic and clinical characteristics
Characteristics | No. of Patients [N = 35, (%)] |
|---|---|
Age, years | |
Mean (SD) | 64.0 (11.8) |
Median (range) | 68 (56–71) |
Gender | |
Male | 21 (60.0) |
Female | 14 (40.0) |
Body mass index (BMI) | |
< 25 | 29 (82.9) |
≥ 25 | 6 (17.1) |
ECOG performance status | |
< 2 | 19 (54.3) |
≥ 2 | 16 (45.7) |
Smoking history | |
Yes | 23 (65.7) |
No | 12 (34.3) |
Primary tumor site | |
Bladder | 19 (54.3) |
Upper tract (renal pelvis, ureter) | 16 (45.7) |
Histology | |
UC without divergent differentiation | 30 (85.7) |
UC with divergent differentiation | 5 (14.3) |
Histological grade at diagnosis | |
Low | 1 (2.9) |
High | 34 (97.1) |
Site of metastases | |
Lymph nodes | 17 (48.6) |
Liver | 2 (5.7) |
Lung | 5 (14.3) |
Bone | 16 (45.7) |
Brain | 1 (2.9) |
Adrenal gland | 1 (2.9) |
Visceral metastases | |
Yes | 21 (60.0) |
No | 14 (40.0) |
Disease status | |
Locally advanced | 5 (14.3) |
Metastatic | 30 (85.7) |
Albumin | |
< 3.5 g/dl | 15 (42.9) |
≥ 3.5 g/dl | 20 (57.1) |
Neutrophil-lymphocyte ratio | |
< 3 | 18 (51.4) |
≥ 3 | 17 (48.6) |
Hemoglobin | |
< 10 g/dl | 9 (25.7) |
≥ 10 g/dl | 26 (74.3) |
Platelet count | |
< 400 000/µl | 32 (91.4) |
≥ 400 000/µl | 3 (8.6) |
Treatment regimens | |
PD-1 inhibitor | 7 (20.0) |
PD-1 inhibitor + chemotherapy | 28 (80.0) |
PD-1 inhibitor + GC | 27 (77.1) |
PD-1 inhibitor + GN | 1 (2.9) |